GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK, or GlaxoSmithKline, has performed badly in the past decade, but its future outlook may not be as bleak. The company has spun off its consumer healthcare segment to focus on the vaccine and HIV segments, which present huge growth opportunities. The current valuation is significantly discounted compared to both peers and its own historical average.

GSK: A Biopharma Giant On Sale

American depositary receipts of GSK jumped after the U.K.-based biopharma company said it had reached a settlement in a lawsuit accusing the firm's discontinued heartburn medicine, Zantac, of causing cancer.

GSK Settles Zantac Cancer Lawsuit Set to Go to Trial Next Month

GSK stock jumped Friday after the British drugmaker said it settled one of thousands of claims that its heartburn drug Zantac caused cancer.

GSK Surges After Settling First Zantac Case, But A 'Conveyor Belt' Of Claims Looms

CarMax

Markets opened lower on Friday. CarMax reported weak financial results that were nevertheless better than most investors had expected.

2 Stocks Defying Friday's Market Downturn

GSK PLC (LSE:GSK, NYSE:GSK) making an out-of-court settlement for a case in California alleging its Zantac heartburn medication caused cancer, is "not a full stop" for the saga, say analysts.  Paying an undisclosed amount to settle the lawsuit, which was filed in California by James Goetz and was scheduled for trial in July, "doesn't have any direct impact on other state level cases", said analyst Dr Sean Conroy at Shore Capita.

GSK out-of-court deal encouraging but 'not the final full stop' in Zantac saga, say analysts

GSK's settlement with a plaintiff in California over claims Zantac can cause cancer avoids a trial and brings it into line with industry peers.

GSK Stock Climbs on Zantac Settlement

Virgin Galactic

Trupanion

Shares of Trupanion Inc. TRUP, -5.73% jumped 16% in premaket trading after the pet-insurance provider announced that California and New York approved double-digit rate increases, saying that the hikes were “necessary in today's rising cost of veterinary care environment.”

Virgin Galactic shares tumble, while Trupanion and GSK climb and other stocks on the move

GSK GSK shares surged 6% in London action as the U.K. pharmaceutical said it reached a settlement over its Zantac heartburn medication litigation with a plaintiff in California ahead of the trial slated to start July 24 in state court. Other companies impacted by Zantac litigation fears, Haleon HLN, +1.28% and Sanofi SAN, +0.91%, also advanced though not by as much.

GSK shares surge after reaching settlement on Zantac ahead of California trial

Shares in GSK PLC (LSE:GSK, NYSE:GSK) rose by 3.4% following the announcement of a confidential settlement reached by the UK pharmaceutical group concerning a US lawsuit. The case claimed that GSK's heartburn medication, Zantac, was responsible for causing cancer.

GSK shares up 3.4% after Zantac settlement

GSK Plc on Friday said it reached a confidential settlement of a litigation in the United States over claims that the British drugmaker's heartburn drug Zantac caused cancer.

GSK reaches settlement in U.S. Zantac litigation

Pfizer

The CDC analysis suggests the shots will reduce the burden of RSV on hospitals in the fall.

Pfizer, GSK RSV shots for older adults may prevent thousands of hospitalizations, CDC analysis says

GSK PLC (LSE:GSK, NYSE:GSK) received a second dose of good this week that augers well for the roll-out of its respiratory syncytial virus (RSV) jab. An advisory committee to the US Centers for Disease Control and Prevention (CDC) has recommended that adults aged 60 and over consider a single dose of GSK or rival Pfizer's RSV vaccine.

GSK and Pfizer RSV jab gets US CDC backing

Bristol-Myers

Bionano Genomics

Inmode Ltd

Inspire Medical Systems Inc

Revance Therapeutics

Viking Therapeutics

Investing in healthcare stocks can be a wise decision for those looking to become wealthy in the long term. Some of the best healthcare stocks to buy are firms that are developing highly effective drugs for prevalent diseases for which there are no real effective treatments.

7 Healthcare Stocks to Make You the Millionaire Next Door

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted in favor of recommending the use of AREXVY (respiratory syncytial virus vaccine, adjuvanted) in adults aged 60 and older using shared clinical decision making. Shared clinical decision making empowers patients in consultation with their healthcare providers to determine whether RSV vaccination is appropria.

US Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices votes to recommend AREXVY for the prevention of RSV disease in adults aged 60 and older with shared clinical decision making

The CDC panel's recommendation moves the U.S. closer to making the respiratory syncytial virus shots from Pfizer and GSK available to seniors.

CDC advisory panel backs use of GSK and Pfizer RSV vaccines in adults over 60

The drugmaker says its RSV shot prevents disease for 18 months.

GSK's RSV Vaccine Could Be Effective for Longer. What That Means.

GlaxoSmithKline's new clinical trial results suggest seniors may only need to take the pharmaceutical company's RSV shot every other year.

GSK says RSV vaccine for older adults provides protection over two seasons

GSK's GSK, -1.51% respiratory syncytial virus vaccine for older adults may protect against disease for two full RSV seasons, according to new results from a phase 3 trial the company released Wednesday. Similar efficacy was seen over two seasons in adults with underlying comorbidities and advancing age, the company said in a release.

RSV vaccine for older adults provides protection over two seasons, GSK says

PHILADELPHIA--(BUSINESS WIRE)--GSK shares positive data for AREXVY, its respiratory syncytial virus (RSV) older adult vaccine, indicating protection over two RSV seasons.

GSK shares positive data for AREXVY, its respiratory syncytial virus (RSV) older adult vaccine, indicating protection over two RSV seasons

A panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Wednesday will vote on whether to recommend the use of recently approved vaccines from Pfizer and GSK to prevent severe respiratory syncytial virus (RSV) infections in older adults.

US CDC advisers weigh use of GSK, Pfizer RSV vaccines in older adults

GSK said its shot, the world's first authorized RSV vaccine, showed protection in older adults for two seasons after a single dose.

RSV Vaccine For Adults Gives Long-Term Protection, GSK Says After Late-Stage Trial

GSK PLC (LSE:GSK, NYSE:GSK)'s respiratory syncytial virus (RSV) vaccine, Arexvy, demonstrated robust long-term protection in a late-stage trial, targeting older adults, the pharma giant revealed on Wednesday. The phase III study revealed the jab worked across two consecutive seasons, inclusive of participants with underlying medical conditions.

GSK: Does new RSV jab have the edge of Pfizer's vaccine?

GSK on Wednesday said its vaccine for the respiratory syncytial virus (RSV), which recently won EU approval, showed strong long-term protection in older adults in a late-stage trial.

GSK's RSV vaccine shows long-term efficacy in late-stage trial

Bio-Techne

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either GSK (GSK) or Techne (TECH). But which of these two stocks presents investors with the better value opportunity right now?

GSK vs. TECH: Which Stock Should Value Investors Buy Now?

PHILADELPHIA--(BUSINESS WIRE)--GSK and Lifetime® Release Short Film Featuring Soleil Moon Frye and Melissa Joan Hart Urging Parents to “Ask2BSure” about Meningitis B.

News for GlaxoSmithKline Stock (GSK)